Published September 29, 2023 | Version v1
Journal article Open

Use of Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Children with Pneumonia and Bronchitis

Authors/Creators

  • 1. Bogomolets National Medical University, Ukraine

Description

In recent years, an increase in the prevalence of antibiotic-associated diarrhea (AAD) in children has been registered. In modern conditions, there are changes in the microbial spectrum of AAD pathogens and their sensitivity to antimicrobial drugs. This indicates the need for further research on the effectiveness and safety of the use of antidiarrheal drugs, in particular Saccharomyces boulardii (SB), in clinical practice.

The objective: to analyze the clinical effectiveness and safety of the use of SB in the prevention of AAD manifestations in children.

Materials and methods. The results of examination and treatment of 84 children aged 1 to 16 years with pneumonia (n=50) and acute bronchitis of bacterial etiology (n=34) were analyzed. Patients comparable in age, gender, etiology and clinical form of acute respiratory disease were divided into two research groups: I (main) group – 44 children who received SB for a course of 10–12 days in complex treatment (antibacterial and symptomatic therapy) and II (control) group – 40 patients who received only antibiotic therapy and did not take probiotic drugs.

During the study, the condition of the digestive tract (appetite, presence of nausea and vomiting, frequency and severity of diarrhea), skin (dryness, drowsiness), nervous system (sleep disturbances, restlessness) was assessed.

Results. At the beginning of the study there was no statistical difference between the frequency of pathological symptoms in the research groups. In the course of treatment, positive dynamics of clinical manifestations of respiratory tract lesions were observed in children in the groups. In the patients of the I group who received SB, on the 10th day all patients had formed stools, while in the II group, on the 10th day diarrhea was detected in 12 (30%) of 40 children (p<0.01). In the dynamics of treatment on the 10th–12th day, the decrease in the number of bifidobacteria (<1010) was found in 2 (6.7%) of 30 children of the I group and in 15 (60%) of the 25 children of the II group (р<0.01).

A decrease in the number of lactobacilli (<107) was found in 1 (3.3%) of 30 children of group I and in 9 (36.0%) of 25 patients of group II (p<0.05). On the 10th–12th day, it was possible to achieve complete normalization of intestinal function in almost all children of the I group. There were no side effects during the use of the drug.

Conclusions. The use of SB simultaneously with antibacterial therapy made it possible to reliably reduce flatulence and intestinal colic in 86.4–88.6% of children on the 5th day of complex treatment. In the main group the frequency and consistency of bowel movements quickly normalized. Such dynamics of clinical symptoms was not observed in the comparison group.

Other

https://family-medicine.com.ua/article/view/289354

Files

Use_of_Saccharomyces_boulardii_to_Prevent_Antibiotic_associated_Diarrhea_in_Children_with_Pneumonia_and_Bronchitis.pdf

Files (1.8 MB)

Additional details

References

  • Kramarov S. Probiotics for diarrhea in children: evidence base. Ukr Med Chasopys. 2019:1.
  • Nasiri MJ, Goudarzi M, Hajikhani B, Ghazi M, Goudarzi H, Pouriran R. Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: A systematic review and meta-analysis. Anaerobe. 2018;50:32–7. doi: 10.1016/j.anaerobe.2018.01.011.
  • Wan CM, Yu H, Liu G, Xu HM, Mao ZQ, Xu Y, et al. A multicenter randomized controlled study of Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in infants and young children. Zhonghua Er Ke Za Zhi. 2017;55(5):349–54. doi: 10.3760/cma.j.issn.0578-1310.2017.05.008.
  • Maidannyk V. Antybityko-asotsiiovana diareia u ditei. Kyiv: Klinichni rekomendatsii.; 2016. 32 p.
  • Marushko Yu, Moskovenko O. Effectiveness and safety of the use of Saccharomyces boulardii in clinical practice. Pediatr.2018;3(46):37–8.
  • Tsyupa I. Saccharomyces bullardia is a probiotic you can trust. Healthy Ukraine. 2020;2:53.
  • Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4(4):CD004827. doi: 10.1002/14651858.CD004827.pub5.
  • Pais P, Almeida V, Yılmaz M, Teixeira MC. Saccharomyces boulardii: What Makes It Tick as Successful Probiotic? J Fungi (Basel). 2020;6(2):78. doi: 10.3390/jof6020078.
  • Ramos SF, Araújo-Neto FC, Aires-Moreno GT, de Araújo DCSA, Lima EDC, de Lyra DP Jr. Causality and avoidability of adverse drug reactions of antibiotics in hospitalized children: a cohort study. Int J Clin Pharm. 2021;43(5):1293–301. doi: 10.1007/s11096-021-01249-8.
  • Duysburgh C, Van den Abbeele P, Morera M, Marzorati M. Lacticaseibacillus rhamnosus GG and Saccharomyces cerevisiae boulardii supplementation exert protective effects on human gut microbiome following antibiotic administration in vitro. Benef Microbes. 2021;12(4):59–73. doi: 10.3920/BM2020.0180.
  • INSTRUCTION MHU Normahut capsules blister, No. 10. 6 wad. Kyiv: Internet issuance; 2019. 1600 p.
  • Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;(12):CD004827. doi: 10.1002/14651858.CD004827.pub4.
  • Jin Y, Yu S, Liu JJ, Yun EJ, Lee JW, Jin YS, et al. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory. Microb Cell Fact. 2021;20(1):160. doi: 10.1186/s12934-021-01644-w.
  • Hayes SR, Vargas AJ. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea. Explore (NY). 2016;12(6):463–6. doi: 10.1016/j.explore.2016.08.015.
  • Investigating Group for Prevention of AAD in Children with Pneumonia by Clostridium Butyricum and Bifidobacterium. Multicenter, randomized, controlled clinical trial on preventing antibiotic-associated diarrhea in children with pneumonia using the live Clostridium butyricum and Bifidobacterium combined Powder. Zhonghua Er Ke Za Zhi. 2012;50(10):732–6.
  • Feng J, Zhang C, Chen H, Chen Z, Chen Y, He D, et al. Shen-Ling-Bai-Zhu-San Enhances the Antipneumonia Effect of Cefixime in Children by Ameliorating Gut Microflora, Inflammation, and Immune Response. Evid Based Complement Alternat Med. 2022;2022:7752426. doi: 10.1155/2022/7752426.
  • Łukasik J, Guo Q, Boulos L, Szajewska H, Johnston BC. Probiotics for the prevention of antibiotic-associated adverse events in children-A scoping review to inform development of a core outcome set. PLoS One. 2020;15(5):e0228824. doi: 10.1371/journal.pone.0228824.
  • Czerucka D, Rampal P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World J Gastroenterol. 2019;25(18):2188–203. doi: 10.3748/wjg.v25.i18.2188.
  • Agamennone V, Krul CAM, Rijkers G, Kort R. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. BMC Gastroenterol. 2018;18(1):103. doi: 10.1186/s12876-018-0831-x.
  • Mourey F, Sureja V, Kheni D, Shah P, Parikh D, Upadhyay U, et al. A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea. Pediatr Infect Dis J. 2020;39(11):e347-e51. doi: 10.1097/INF.0000000000002849.
  • Nenkovskiy S, Neyankovskaya O, Yatsula M, Gorodilovskaya M. Peculiarities of ingestion of probiotics in antibiotic association of diarrhea in children. Healthy Kids. 2020;15(2):55–61.
  • Shadrin O, Marushko T, Marushko R. Ways to prevent antibiotic-associated diarrhea in children of early age. Healthy Kids. 2018;13(5):11–5.
  • Shan LS, Hou P, Wang ZJ, Liu FR, Chen N, Shu LH, et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes. 2013;4(4):329–34. doi: 10.3920/BM2013.0008.
  • Mourey F, Sureja V, Kheni D, Shah P, Parikh D, Upadhyay U, et al. A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea. Pediatr Infect Dis J. 2020;39(11):e347–e51. doi: 10.1097/INF.0000000000002849.
  • Sen S, Mansell TJ. Yeasts as probiotics: Mechanisms, outcomes, and future potential. Fungal Genet Biol. 2020;137:103333. doi: 10.1016/j.fgb.2020.103333.
  • Wan CM, Yu H, Liu G, Xu HM, Mao ZQ, Xu Y, et al. A multicenter randomized controlled study of Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in infants and young children. Zhonghua Er Ke Za Zhi. 2017;55(5):349–54. doi: 10.3760/cma.j.issn.0578-1310.2017.05.008.
  • Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42(7):793–801. doi: 10.1111/apt.13344.
  • Zhang J, Wan S, Gui Q. Comparison of safety, effectiveness and serum inflammatory factor indexes of Saccharomyces boulardii versus Bifidobacterium triple viable in treating children with chronic diarrhea: a randomized trial. Transl Pediatr. 2021;10(6):77–1685. doi: 10.21037/tp-21-195.
  • Pais P, Almeida V, Yılmaz M, Teixeira MC. Saccharomyces boulardii: What Makes It Tick as Successful Probiotic? J Fungi (Basel). 2020;6(2):78. doi: 10.3390/jof6020078.